ACT FAMCICLOVIR 250 MG — DIN 02305690
FAMCICLOVIR : 250 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is ACT FAMCICLOVIR?
ACT FAMCICLOVIR 250 MG contains FAMCICLOVIR : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02305690, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 03-Jul-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ACT FAMCICLOVIR used for?
Treatment of acute herpes zoster (shingles); treatment/suppression of recurrent genital herpes in immunocompetent adults; recurrent mucocutaneous herpes simplex in HIV-infected patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Famciclovir cost around the world?
Famciclovir is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 7 | 26 | AUD███.██ |
| United States | acquisition | 3 | 18 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 12 | EUR███.██ |
| Spain | PVP con IVA (public price) | 9 | 9 | EUR███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| South Africa | single exit price | 5 | 6 | ZAR███.██ |
| Saudi Arabia | public | 3 | 4 | SAR███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
90 pack listings across 48 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Famciclovir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Famciclovir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Famciclovir, across 36 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 3 | 3 | APO-FAMCICLOVIR | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 3 | 3 | FAMVIR | Sourceable in Canada |
| AURO PHARMA INC | 3 | 0 | AURO-FAMCICLOVIR | No marketed DIN |
| AVANSTRA INC | 3 | 0 | AVA-FAMCICLOVIR | No marketed DIN |
| COBALT PHARMACEUTICALS COMPANY | 3 | 0 | FAMCICLOVIR | No marketed DIN |
| DOMINION PHARMACAL | 3 | 0 | DOM-FAMCICLOVIR | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-FAMCICLOVIR | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-FAMCICLOVIR | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-FAMCICLOVIR | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | FAMCICLOVIR | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | SANDOZ FAMCICLOVIR | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | ACT FAMCICLOVIR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Aluminum foil-PVC/PVDC unit dose blister packages (125 mg: 10s; 250 mg: 30s; 500 mg: 21s) and HDPE bottles of 100 tablets (500 mg only). |
| Storage | Store at room temperature (15-30°C). Protect from light. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Famciclovir |
|---|---|
| ATC code | J05AB09 |
| AHFS class | 08:18.32 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02305690 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2305690 |
| Brand name | ACT FAMCICLOVIR |
| Generic / active ingredient | FAMCICLOVIR : 250 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | J05AB09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AB |
| Current status | DORMANT |
| Status date | 03-Jul-2024 |
| Original market date | 2008-10-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Herpes zoster: 500 mg 3x/day for 7 days. Recurrent genital herpes: 125 mg 2x/day for 5 days. Suppression: 250 mg 2x/day. HIV-infected (mucocutaneous): 500 mg 2x/day for 7 days. Take with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to famciclovir or to any ingredient in the formulation or component of the container.
Warnings and precautions
Dosage adjustment required in renal impairment. Efficacy not established for first episode genital herpes or disseminated zoster. May cause dizziness/confusion; caution when driving.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 36 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FAMCICLOVIR | 500 MG | TABLET | APOTEX INC | MARKETED | 02292068 |
| APO-FAMCICLOVIR | 125 MG | TABLET | APOTEX INC | MARKETED | 02292025 |
| APO-FAMCICLOVIR | 250 MG | TABLET | APOTEX INC | MARKETED | 02292041 |
| FAMVIR | 250 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | 02229129 |
| FAMVIR | 500 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | 02177102 |
| FAMVIR | 125 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | 02229110 |
| ACT FAMCICLOVIR | 500 MG | TABLET | TEVA CANADA LIMITED | DORMANT | 02305704 |
| ACT FAMCICLOVIR | 125 MG | TABLET | TEVA CANADA LIMITED | DORMANT | 02305682 |
| AURO-FAMCICLOVIR | 125 MG | TABLET | AURO PHARMA INC | APPROVED | 02431564 |
| AURO-FAMCICLOVIR | 250 MG | TABLET | AURO PHARMA INC | APPROVED | 02431572 |
2 · Same class — other molecules in ATC J05AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Valaciclovir | AG-VALACYCLOVIR · APO-VALACYCLOVIR · AURO-VALACYCLOVIR · BIO-VALACYCLOVIR · +17 more | 36 | 22 | Yes |
| Acyclovir | ACYCLOVIR · ACYCLOVIR SODIUM FOR INJECTION · ACYCLOVIR SODIUM INJECTION · ACYCLOVIR-200 · +17 more | 48 | 15 | Yes |
| Famciclovir | ACT FAMCICLOVIR · APO-FAMCICLOVIR · AURO-FAMCICLOVIR · AVA-FAMCICLOVIR · +7 more | 36 | 6 | Yes |
| Valganciclovir | APO-VALGANCICLOVIR · AURO-VALGANCICLOVIR · MINT-VALGANCICLOVIR · MYLAN-VALGANCICLOVIR · +3 more | 9 | 6 | Yes |
| Ganciclovir | CYTOVENE · CYTOVENE - CAP 250MG · CYTOVENE INJ 500MG/VIAL · CYTOVENE, 500 MG · +2 more | 9 | 4 | Yes |
| Remdesivir | VEKLURY | 2 | 1 | Yes |
| Cidofovir | MAR-CIDOFOVIR | 1 | 1 | Yes |
| Brincidofovir | TEMBEXA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACT FAMCICLOVIR called?
The same molecule, Famciclovir, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Famvir | Latin | Australia, Bahrain, South Africa |
| APO-Famciclovir | Latin | Australia |
| FAMCICLOVIR-WGR | Latin | Australia |
| Ezovir | Latin | Australia |
| Zostivr | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.